ClinConnect ClinConnect Logo
Search / Trial NCT03674255

Echocardiography: Value and Accuracy at REst and STress

Launched by UNIVERSITY OF OXFORD · Sep 14, 2018

Trial Information

Current as of July 22, 2025

Enrolling by invitation

Keywords

Stress Echocardiography Blood Biomarkers Extracellular Vesicles Imaging Biomarkers Machine Learning Artificial Intelligence Ischaemic Heart Disease Coronary Artery Disease Angina Pectoris

ClinConnect Summary

Study Overview:

• Design

EVAREST is a multi-centre observational study comparing accuracy of novel quantitative stress echocardiography biomarkers for prediction of 12 month outcome against standard clinical interpretation.

• Scientific Justification

Coronary artery disease affects 2.3 million people in the UK and is responsible for 66 000 deaths each (BHF, 2018). As such, early diagnosis and intervention is crucial for saving lives and improving people's quality of life. Stress echocardiography is a commonly used, non-invasive imaging test used for detection of prognostically significa...

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Patients must be undergoing a stress echocardiogram to investigate the presence of ischaemic heart disease (groups 1-3).
  • Patients must be able to provide informed consent.
  • Patients must be aged over 18 years of age.
  • Exclusion Criteria:
  • Patients undergoing stress echocardiography to assess valvular function.
  • Patients who are unwilling or unable to provide informed consent.
  • Patients aged under 18 years of age.

About University Of Oxford

The University of Oxford, a prestigious institution renowned for its excellence in research and education, serves as a leading clinical trial sponsor dedicated to advancing medical science and improving patient care. With a rich history of innovation and a multidisciplinary approach, the university leverages its extensive expertise in various fields, including medicine, public health, and biomedical research, to conduct rigorous clinical trials. Collaborating with healthcare professionals, industry partners, and regulatory bodies, the University of Oxford aims to translate groundbreaking research findings into effective therapies and interventions, contributing to the global effort of enhancing health outcomes.

Locations

Patients applied

0 patients applied

Trial Officials

Paul Leeson

Principal Investigator

Cardiovascular Clinical Research Facility, University of Oxford

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials